Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (257)	10/30/2003 2:34:41 PM
From: Icebrg	Read Replies (1) \| Respond to of 362

* Alcoholism treatment options -- A pair of studies presented different ways of delivering drug therapies to recovering alcoholics. While pills exist that can combat alcohol addiction, the biggest problem is that people stop taking their medications and revert back to drinking. The two new options being studied are an injectable gel and an implanted device, both of which would give doctors more control over their patients' treatments. A gel form of Naltrexone, a drug used to treat drug and alcohol addiction, was found to be steadily released in test mice, according to researchers at the University of Tennessee and Mississippi State University. Rods of Nalmefene, a anti-alcoholism drug, were implanted in mice and found to release the substance in a steady state during a two-month study, according to research from Titan Pharmaceuticals, the Southwest Research Institute and Behavioral Pharma, Inc. sltrib.com